Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

LB54640

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Rhythm · Phase 2 · Completed · Enrollment 28

NCT06046443

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Bivamelagon Low dose (200 milligrams [mg])n/rn/rn/rn/r
Bivamelagon Middle dose (400 mg)n/rn/rn/rn/r
Bivamelagon High dose (600 mg)n/rn/rn/rn/r
Placebon/rn/rn/rn/r
Open-label Bivamelagonn/rn/rn/rn/r

Not shown

  • Bivamelagon Low dose (200 milligrams [mg]): endpoint not reported
  • Bivamelagon Middle dose (400 mg): endpoint not reported
  • Bivamelagon High dose (600 mg): endpoint not reported
  • Placebo: endpoint not reported
  • Open-label Bivamelagon: endpoint not reported